eculizumab (Soliris) Report issue

Biologics mAb Orphan Drug FDA Approved FDA First in Class Priority Review FDA

Active Ingredient History

NOW
  • Now
Pexelizumab is a drug designed to reduce side effects of coronary artery bypass grafting and angioplasty, among other types of cardiac surgery. It is a single chain variable fragment of a monoclonal antibody targeted against component 5 of the complement system.   Wikipedia

More Chemistry
  • Mechanisms of Action:
  • Multi-specific: No
  • Black Box: Yes
  • Availability: Prescription Only
  • Delivery Methods: Parenteral
  • Pro Drug: No

Drug Pricing (per unit)

Australia

$4373.1804

United States

$4981.6100 - $6031.3200
More Pricing Detail

Note: This drug pricing data is preliminary, incomplete, and may contain errors.

5g1.1 | 5g1.1-sc | eculizumab | h5g1.1 | h5g1.1-sc | h5g1.1 scfv | h5g1.1-scfv | h5g1.1 scfv (cdr) | h5g1.1vhc+h5g1.1vlc | pexelizumab | soliris

Feedback

Data collection and curation is an ongoing process for CDEK - if you notice any information here to be missing or incorrect, please let us know! When possible, please include a source URL (we verify all data prior to inclusion).

Report issue